BIOLINERX LTD/S (NASDAQ:BLRX) shares fell 26.1% during trading on Thursday . The company traded as low as $1.55 and last traded at $2.04, 1,131,490 shares changed hands during trading. An increase of 1,337% from the average session volume of 78,758 shares. The stock had previously closed at $2.76.
BLRX has been the topic of a number of recent analyst reports. HC Wainwright restated a “neutral” rating on shares of BIOLINERX LTD/S in a research note on Wednesday, August 7th. Zacks Investment Research downgraded shares of BIOLINERX LTD/S from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $4.75.
The company has a debt-to-equity ratio of 0.18, a current ratio of 3.14 and a quick ratio of 3.14. The firm has a market capitalization of $20.64 million, a P/E ratio of -0.65 and a beta of 1.62. The firm’s fifty day moving average price is $2.66 and its 200-day moving average price is $2.20.
About BIOLINERX LTD/S (NASDAQ:BLRX)
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Further Reading: Margin
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.